IP Library › Granted Patent US 9,511,087
Granted Patent B2
US 9,511,087 · App. 14/239,943 · Granted Dec 6, 2016

Use of antithrombin in extracorporeal membrane oxygenation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,511,087
App. No.
14/239,943
Granted
Dec 6, 2016
Kind
B2
Abstract

In one aspect, the disclosure provides methods of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®.

Claims (15)

1. A method of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation, the method comprising:

administering to a subject having extracorporeal membrane oxygenation a therapeutically effective amount of recombinant antithrombin to suppress blood clotting and/or prevent hemorrhage.

2. The method of claim 1 , wherein the antithrombin has a high mannose glycosylation pattern.

3. The method of claim 1 , wherein the antithrombin has a high fucose glycosylation pattern.

4. The method of claim 1 , wherein the antithrombin comprises GalNac (N-acetylgalactosamine).

5. The method of claim 1 , wherein the antithrombin is transgenically produced antithrombin.

6. The method of claim 5 , wherein the antithrombin is transgenically produced in a goat.

7. The method of claim 1 , wherein the antithrombin is a transgenic human alpha-antithrombin that is produced in a goat mammary gland.

8. The method of claim 1 , wherein the antithrombin is administered at a dose of 6 units per kg.

9. The method of claim 1 , wherein the antithrombin is administered at a dose of 80 units per kg.

10. The method of claim 1 , wherein the antithrombin is administered at a dose of 295 units per kg.

11. The method of claim 1 , wherein the antithrombin is administered at a dose sufficient to maintain a level of antithrombin activity present in the blood at the time of initiation of extracorporeal membrane oxygenation.

12. The method of claim 1 , wherein the antithrombin is administered in one dose.

13. The method of claim 1 , wherein the antithrombin is administered by a bolus followed by continuous infusion.

14. The method of claim 1 , further comprising administering heparin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2014
From: LOWRY, SIMON; FRIELING, JOHAN
To: REVO BIOLOGICS, INC.
Reel/Frame 032311/0431 →